Fortis Healthcare Limited (NSE: FORTIS) reported a Revenue from Operations of ₹1,559.88 Crores, an increased of 6% growth from the previous year.
Categories
Diagnostics
Thyrocare Technologies net profit declines by 43% in the December 2022 quarter
Net profit of Thyrocare Technologies declined by 43.47% to INR 13 crore in the quarter ended December 2022 as against INR 23
Dr Lal PathLabs Ltd Q3 FY23 Earnings Conference Call Insights
Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q3 FY23 Earnings Concall Q&A Highlights: [00:12:28] Dheeresh Pathak from WhiteOak asked about the
Vijaya Diagnostic: A King in the Making
“The second quarter saw a healthy improvement in the demand for Non-COVID business across all segments. The Company managed to enhance its
Krsnaa Diagnostics Ltd (KRSNAA) Q2 FY23 Earnings Concall Transcript
Krsnaa Diagnostics Ltd (NSE:KRSNAA) Q2 FY23 Earnings Concall dated Nov. 10, 2022 Corporate Participants: Yash Prithviraj Mutha C.A. -- Whole-Time Director Pawan
Dr Lal PathLabs Ltd Q2 FY23 Earnings Conference Call Insights
https://youtu.be/lAaNZKEvjOc Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q2 FY23 Earnings Concall Q&A Highlights: [00:16:43] Rahul Agarwal with Incred Capital enquired
Earnings Infographic: Dr. Lal PathLabs Q1 2023 revenue and profit decline
Dr. Lal PathLabs Ltd (NSE: LALPATHLAB), a leading provider of diagnostic and related healthcare services, has reported lower revenues and earnings for
Dr Lal PathLabs Limited Research Report
Stock Data Ticker: LALPATHLAB Exchange : NSE BSE: 539524 Industry: Diagnostic Price Performance Last 7 days 8.70% YTD -38.28% Last 12 months
Dr Lal PathLabs Ltd Q1 FY23 Earnings Conference Call Insights
https://youtu.be/GyHJJGLWdjg Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q1 FY23 Earnings Concall Management Update: LALPATHLAB said it clocked the highest quarterly
Research Summary Dr Lal PathLabs Limited Q4 FY 2022
Overview Dr Lal PathLabs Limited is an Indian diagnostic company. It was incorporated in 1949. The headquarters is situated in Delhi, India. It
Krsnaa Diagnostics Ltd Q4 FY22 Earnings Conference Call Insights
https://youtu.be/oafWwDciC8w Key highlights from Krsnaa Diagnostics Ltd (KRSNAA) Q4 FY22 Earnings Concall Q&A Highlights: Praveen Sahay of Edelweiss asked that why the
Dr Lal PathLabs Ltd Q4 FY22 Earnings Conference Call Insights
https://youtu.be/XGfFd6kLFCE Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q4 FY22 Earnings Concall Management Update: LALPATHLAB said it saw significant shift towards
Dr Lal PathLabs Ltd Q3 FY22 Earnings Conference Call Insights
https://www.youtube.com/watch?v=q_lILVipT-E Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q3 FY22 Earnings Concall Management Update: The company is enhancing access of its
IPO News: Vijaya Diagnostic plans to offer up to 3.57 crore shares for sale
Diagnostic services have become the cornerstone of healthcare, especially for recommending treatments and monitoring post-treatment recovery. The diagnostics industry in India, valued